{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/antiplatelet-treatment/","result":{"data":{"firstChapter":{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field a94d4549-6863-480a-b5c8-3f92929f2c1d --><h1>Antiplatelet treatment: Summary</h1><!-- end field a94d4549-6863-480a-b5c8-3f92929f2c1d -->","htmlStringContent":"<!-- begin item 76086756-eabc-4356-a62c-54ece86f17a0 --><!-- begin field 438847f0-928c-4734-a290-59685033d755 --><ul><li>Antiplatelet treatment is drug treatment that decreases platelet aggregation and inhibit thrombus formation in the arterial circulation. </li><li>Four main types of antiplatelet drugs are available:<ul><li>Aspirin — this irreversibly inhibits cyclo-oxygenase and blocks the production of thromboxane. </li><li>Clopidogrel, prasugrel and ticagrelor — these are are thienopyridines. They inhibit the binding of adenosine diphosphate to its platelet receptor, this is thought to inhibit platelet aggregation by blocking activation of the glycoprotein IIb/IIIa pathway.</li><li>Dipyridamole — this has both antiplatelet and vasodilatory properties. It inhibits uptake of adenosine into erythrocytes, platelets, and endothelial cells, resulting in an increased extracellular concentration of adenosine, which is a potent inhibitor of platelet activation and aggregation. It may also act by inhibiting the breakdown of cyclic guanosine monophosphate.</li><li>Glycoprotein IIb/IIIa inhibitors (for example, abciximab, eptifibatide, and tirofiban) block the binding of fibrinogen to glycoprotein IIb/IIIa receptors on the platelet. They are given intravenously in secondary care and are not discussed in this topic.</li></ul></li><li>The main indications for antiplatelets are: <ul><li>The primary prevention of atherothrombotic events in people who are at high risk. </li><li>The secondary prevention of atherothrombotic events in people with acute coronary syndrome (ACS), angina, peripheral arterial disease (PAD), and atrial fibrillation (AF) (although anticoagulants are usually used).</li><li>The secondary prevention of cardiovascular events in people after myocardial infarction (MI), stent implantation, stroke or transient ischaemic attack (TIA).</li><li>The prevention of atherothrombotic events in people undergoing percutaneous coronary intervention (PCI). </li></ul></li><li>Antiplatelets should not be prescribed routinely for the primary prevention of cardiovascular disease, however, they may be considered in people at high risk of stroke or myocardial infarction.</li><li>Antiplatelet treatment for secondary prevention of CVD should be prescribed for people with:<ul><li>Angina — aspirin 75 mg. Clopidogrel 75 mg daily should be considered for people unable to take aspirin. </li><li>AF — dual antiplatelet therapy (DAPT) of aspirin 75 mg daily plus clopidogrel 75 mg daily may be suitable for people who are unable or unwilling to take anticoagulants. </li><li>ACS which is medically managed — aspirin 75 mg daily plus ticagrelor 90 mg twice a day for 12 months. </li><li>PCI for people with ACS — aspirin 75 mg in combination with either ticagrelor 90 mg twice a day, or prasugrel 10 mg daily. Clopidogrel 75 mg daily should be prescribed if prasugrel or ticagrelor are unsuitable. </li><li>PCI in people with stable coronary artery disease — aspirin 75 mg daily plus clopidogrel 75 mg daily. Ticagrelor or prasugrel may be considered instead of clopidogrel where appropriate.</li><li>ACS who are undergoing coronary artery bypass grafting (CABG) — aspirin 75 mg in combination with ticagrelor 90 mg twice a day, or prasugrel 10 mg daily. Clopidogrel 75 mg daily should be prescribed if prasugrel or ticagrelor are not suitable.<ul></ul></li><li>Stroke, or TIA — clopidogrel 75 mg daily is the preferred antiplatelet. Modified-release dipyridamole (200 mg twice a day) should be prescribed with combined with aspirin 75 mg if clopidogrel is unsuitable. </li><li>PAD, or multivascular disease — clopidogrel 75 mg daily is the preferred antiplatelet. Aspirin 75 mg alone should be prescribed if clopidogrel is unsuitable. </li></ul></li></ul><!-- end field 438847f0-928c-4734-a290-59685033d755 --><!-- end item 76086756-eabc-4356-a62c-54ece86f17a0 -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","aliases":[],"chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","slug":"management","fullItemName":"Management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","aliases":[],"topicSummary":"Antiplatelet treatment prevents the formation of blood clots by preventing platelet aggregation.","lastRevised":"Last revised in August 2020","nextPlannedReviewBy":"2023-09-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2023-08","nextPlannedReviewByDisplay":"August 2023","specialities":[{"id":"fe645ae3-9536-5dfb-8c84-285b62195550","name":"Cardiovascular","slug":"cardiovascular"},{"id":"45db1917-4d65-58d8-af3d-568321e486ed","name":"Drugs and devices","slug":"drugs-devices"},{"id":"2454765b-1b2d-53fc-b288-17b66486f41a","name":"Preventative medicine","slug":"preventative-medicine"}],"chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","slug":"management","fullItemName":"Management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947"}},"staticQueryHashes":["3666801979"]}